论文部分内容阅读
目的 探讨海力特联合病毒唑治疗慢性乙型肝炎的临床疗效。方法 用海力特联合大剂量病毒唑治疗慢性乙型肝炎６０例，并与６０例用一般保肝药物治疗的慢性乙型肝炎进行了观察对比。结果 治疗组总有效率为８８．３３％，明显优于对照组（７１．６２％），（Ｐ＜０．０５）。其ＡＬＴ，γＧＴ，Ａ／Ｇ复常率分别为９０％，９５．２５％，６８．４２％，均明显优于对照组。另外对ＨＢＶ也有一定的抑制作用。ＨＢｅＡｇ和ＨＢＶＤＮＡ阴转率分别为３８．００％和３８．４６％，均高于对照组。结论 海力特联合病毒唑对改善慢性乙型肝炎患者临床症状、肝功均有较好疗效，且具有一定的ＨＢｅＡｇ，ＨＢＶＤＮＡ转阴作用。
Objective To investigate the clinical effect of combination of Ribavirin and Ribavirin in the treatment of chronic hepatitis B. Methods 60 cases of chronic hepatitis B were treated with combination of Hyperthermia and high-dose ribavirin, and compared with 60 cases of chronic hepatitis B treated with general hepatoprotective drugs. Results The total effective rate in the treatment group was 88.33%, which was significantly better than that in the control group (71.62%) (P <0.05). The ALT, γ GT, A / G normalization rates were 90%, 95.25%, 68.42%, were significantly better than the control group. In addition, there is also a certain degree of inhibition of HBV. The negative conversion rates of HBeAg and HBV-DNA were 38.00% and 38.46%, respectively, which were higher than those of the control group. Conclusion Combination of HTL and ribavirin can improve the clinical symptoms and liver function of patients with chronic hepatitis B, and has certain HBeAg and HBV DNA negative effects.